NEW YORK--(BUSINESS WIRE)--ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that ERBITUX® (cetuximab) has been commercially launched in Japan for use in treating patients with advanced or metastatic colorectal cancer (mCRC). The launch of ERBITUX in Japan is the result of a co-development and co-commercialization agreement between ImClone, Bristol-Myers Squibb Company and Merck KGaA, Darmstadt, Germany.
